Research Analysts Set Expectations for Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Equities research analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of Surmodics in a report issued on Monday, November 25th. Zacks Research analyst D. Dey now anticipates that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.12). The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q1 2026 earnings at $0.22 EPS.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%. The firm had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million.

Several other analysts have also recently issued reports on SRDX. StockNews.com initiated coverage on shares of Surmodics in a research report on Saturday, November 23rd. They set a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

SRDX stock opened at $39.54 on Thursday. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The firm has a market capitalization of $566.61 million, a P/E ratio of -48.81 and a beta of 1.20. The company has a fifty day simple moving average of $38.50 and a two-hundred day simple moving average of $39.58. The company has a quick ratio of 3.22, a current ratio of 3.96 and a debt-to-equity ratio of 0.25.

Institutional Trading of Surmodics

Several institutional investors have recently added to or reduced their stakes in SRDX. Lazard Asset Management LLC grew its stake in shares of Surmodics by 13.4% during the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after buying an additional 673 shares during the last quarter. Quest Partners LLC boosted its holdings in Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after acquiring an additional 1,071 shares during the period. Los Angeles Capital Management LLC grew its position in Surmodics by 3.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 36,425 shares of the company’s stock valued at $1,531,000 after acquiring an additional 1,221 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Surmodics by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company’s stock worth $4,511,000 after purchasing an additional 1,491 shares during the period. Finally, Longfellow Investment Management Co. LLC bought a new stake in shares of Surmodics during the third quarter worth $67,000. Institutional investors own 96.63% of the company’s stock.

Insider Activity

In related news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now directly owns 70,350 shares in the company, valued at approximately $2,774,604. This represents a 9.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.90% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).